Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Teva

Chicago is seeing an increase in fatal meth overdoses. Here’s why.

110 people in Chicago died from methamphetamine overdoses in 2021, a steep rise from 47 in 2019. The fatal overdoses are linked to a rise in demand, increased supply and deadlier “cocktails” as dealers cut the drug with fentanyl and cocaine.

Chicago Sun-Times

Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling

Teva Pharmaceutical said Monday it plans to make a knockoff of Axsome Therapeutics' new depression treatment, leading AXSM stock to tumble.

Investors Business Daily

Teva Guides To Its First Year Of Growth Since 2017 — But Shares Tumbled On This Caveat

Teva expects 2023 sales to grow for the first time in six years, but the guidance comes with one notable caveat and Teva stock fell.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

No. 1 IBD 50 Stock Catalyst Tanks As Teva Looks To Knock Off Its Only Product

Teva said Monday it plans to knock off Catalyst's only approved drug and CPRX stock — which has sat atop the IBD 50 for weeks — crashed.

Investors Business Daily

4 Pharma Stocks You Shouldn’t Think Twice About Buying in 2023

Pharma sector usually performs relatively well amid market turmoil due to the inelastic demand for its offerings. Moreover, increased technological advancements should boost the industry’s growth. Hence, pharma stocks Eli Lilly (LLY), AstraZeneca (AZN), Zoetis (ZTS), and Teva Pharmaceutical (TEVA) might be worth buying in 2023. Read more.

StockNews.com

‘It’s fun, it’s versatile, it’s functional’: terry towelling’s time in the sun

Emerging designers are putting a sustainable twist on the quintessentially 70s fabric, that’s practical at the beach and playful off it

The Guardian - AU

4 Stocks to Buy Before the Next Big Bull Rally

Cooling inflationary pressures and the Fed’s indication of a slower pace of rate hikes ahead could generate a potential bull rally this month. So, we believe investors should load up on fundamentally strong stocks General Motors Company (GM), BorgWarner Inc. (BWA), Teva Pharmaceutical Industries Limited (TEVA), and Rambus Inc. (RMBS).…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

4 Stocks to Amplify Your Portfolio in Q4

With investors regaining confidence in the markets amid cooling down inflation, fundamentally strong stocks CSX Corporation (CSX), Teva Pharmaceutical Industries (TEVA), Celestica Inc. (CLS), and DLH Holdings (DLHC) may be ideal investments to capitalize on their potential rebound. Continue reading….

StockNews.com

Troubled FTX Faces SEC Probe And 'Urgently Needs' $8B To Avoid Bankruptcy, NIO Posts Wider Q3 Loss, AstraZeneca Ditches US Application Submission For COVID-19 Shot: Top Stories Thursday, Nov. 11

Bloomberg

Benzinga

4 Health Care Stocks That Could Keep Your Portfolio From Needing a Check-Up

The healthcare industry tends to withstand macroeconomic pressure better than other industries due to the almost inelastic demand for medical products and services. With a recession expected next year, investors could look to capitalize on the defensive characteristics and long-term prospects of the industry by investing in quality medical stocks…

StockNews.com

New York could get $524M under opioid settlements with Teva

New York Attorney General Letitia James says the state will receive up to $524 million from drugmaker Teva to settle claims that the company contributed to the U.S. opioid epidemic

The Independent UK

Buy These 2 Growth Stocks Before They Boom

The red-hot inflation and the Fed’s hawkish stance are raising the possibility of a recession. However, historical trends suggest that the market could experience a rebound later this month or early next month. So, we think it could be wise to invest in growth stocks Teva Pharmaceutical (TEVA) and Forrester…

StockNews.com

Blame the Government for the Adderall Shortage

Limiting the supply of a controlled substance does not remove demand. Users simply look elsewhere, including more unsavory sources.

Reason

US shortage of Adderall is due to increased demand, FDA and drug-makers say

FDA says supply does not meet demand and drug-maker says backorders are due to ‘significant rise’ in prescription rates

The Guardian - US

Get all your
news in one place.

100’s of premium titles.
One news app.

The Street

FDA Announces Shortage of This Crucial Drug

Teva and the FDA seem to have differing views on what is causing the shortage.

Los Angeles Times

Commentary: Prevent a legal Catch-22 that could push thousands of generic drugs off the market

Carvedilol could be the poster child for how to lower drug prices. Since 2007, more than 20 million patients with cardiovascular conditions have enjoyed generic versions of the popular beta-blocker, which cost 2 cents a dose compared with $4.81 for the brand-name product. Patents on the drug Coreg, dating back…

StockNews.com

3 Health Care Stock Under $50 You Can Buy Today

The healthcare industry is anticipated to grow significantly in the coming years, thanks to strong demand amid rising chronic diseases, technological advancements, and rising healthcare spending. Therefore, we think fundamentally sound healthcare companies Pfizer (PFE), GSK Plc (GSK), and Teva Pharmaceutical (TEVA), which are currently trading under $50, could be…

StockNews.com

1 Stock Warren Buffett Might Have Sold Too Soon

Warren Buffett’s diversified holding company Berkshire Hathaway exited its position in drugmaker TEVA by the end of 2021 at a loss of approximately $365 million on its four-year-long bet. However, Buffett appears to have exited to stock too soon as TEVA witnessed a significant reversal this year, gaining 34.5% year-to-date.…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours:

Investors Business Daily

Teva Pharmaceutical Soars After Inking More Than $4 Billion In Opioid Deals

Teva Pharma inked settlement deals worth upward of $4 billion for its role in the opioid crisis, and Teva stock skyrocketed on Wednesday.

Benzinga

Benzinga Before The Bell: Twitter Shareholder Proposal Date Set, T-Mobile's Strong FY22 Outlook, Shopify's Job Cuts And Other Top Financial Stories Wednesday, July 27

Reuters Monkeypox Emergency Could Last Months, According To Experts

Tribune News Service

Teva Pharmaceutical will pay over $4 billion in opioid settlement

Teva Pharmaceutical Industries Ltd. said it had agreed to pay more than $4 billion to resolve thousands of lawsuits filed against the drugmaker by state and local governments over its highly addictive opioid painkillers.

AFP

Israel's Teva reaches potential $4.25 bn US opioid settlement

Washington (AFP) - Israeli generic drug maker Teva has reached an agreement in principle to pay $4.25 billion over 13 years to settle a series of court cases over its role in the US opioid epidemic.

StockNews.com

3 Stocks to Grab Before They Potentially Turn Around

Concerns over red-hot inflation and the Fed’s hawkish stance is raising the possibility of a recession. However, BofA believes the ongoing bear market provides attractive opportunities for long-term investors. So, we think it could be wise to invest in Zoom Video (ZM), Teva Pharmaceutical (TEVA), and Trulieve Cannabis (TCNNF) which…

The Independent UK

Allergan, Teva to pay $54M in San Francisco opioid lawsuit

Opioid makers Allergan and Teva have agreed to pay $54 million in cash and overdose reversal drugs to settle a federal lawsuit brought by San Francisco

1 2 3 4

People

Dipanjan BanchurSince

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.